Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization of $246K in Q2 FY2026
Q2 FY2026 depreciation & amortization was $246K.
Context
- Depreciation & amortization amounted to 59.6% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 804K USD
- Year-over-year change
- +156.9%
- 1-year CAGR
- +156.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 804K | +156.9% |
| FY2024 | 2024-12-31 | 313K | — |
Depreciation & Amortization vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 depreciation & amortization of $804K is the 5th largest of the 10 companies compared; the peer median is $704K.
- Its year-over-year change of +156.9% is the 2nd highest of 9, against a peer median of +6.0%.
- Depreciation & amortization amounts to 59.6% of revenue for ATTO, versus a peer median of 10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $3.08M | +114.9% | +496.0% | — | |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $1.36M | — | — | 13.6% |
| FY2025 | $804K | +156.9% | — | 59.6% | |
| FY2025 | $704K | +6.7% | -11.4% | 1100.0% | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
| LTM Mar 2026 | $305K | -36.9% | +1.9% | 0.6% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $163K | +129.6% | -10.0% | — |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +229.4% | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $704K | +6.0% | +1.2% | 10.0% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.